Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell lineNicola Coppola, Antonio De Luca, Angelica Perna et al.|Journal of Cellular Physiology|2018Cited by 36
Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life SettingPaolo Maggi, Paolo Bonfanti, Elena Ricci et al.|Viruses|2023Cited by 17
Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA StudyPaolo Bonfanti, Barbara Menzaghi, Giancarlo Orofino et al.|Viruses|2024Cited by 13
Effects of treatment with Maraviroc a CCR5 inhibitor on a human hepatic stellate cell lineNicola Coppola, Antonio De Luca, Angelica Perna et al.|Digestive and Liver Disease|2017Cited by 8
Lipids and Body Mass Index in Antiretroviral‐Experienced People With HIV on Doravirine‐Based Treatments: A Comparison Between Dual or Triple Regimen Versus Bictegravir‐Based Triple RegimenPaolo Maggi, Addolorata Masiello, Barbara Menzaghi et al.|AIDS Research and Treatment|2025Cited by 0